Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival


22 Nov 2020


e-Poster Display Session



Tumour Site

Central Nervous System Malignancies


Paulo Luz


Annals of Oncology (2020) 31 (suppl_6): S1407-S1415. 10.1016/annonc/annonc368


P.J.C. Luz1, I.C. Gomes Fernandes2, L. Bretes1

Author affiliations

  • 1 Medical Oncology Department, Centro Hospitalar Universitário do Algarve, 8000-386 - Faro/PT
  • 2 Dept. Oncologia Médica, Hospital Nossa Senhora do Rosário (Centro Hospitalar Barreiro Montijo, EPE), 2834-003 - Barreiro/PT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 439P


GBM is the most common and agressive primary brain tumor with a median survival around 12-14 months. Detection of prognostic factors will be very important in planning and selecting treatment for patients with this disease. Association of TP53 mutations and Ki67 proliferation index with survival outcome in GBM patients has not been consistente. Aim: the aim of our study were to determine the expression of p53 and Ki67 in our cohort of GBMs patients, and to determine their correlation with patient survival.


This study is based on samples prospectively collected from 65 patients with glioblastoma. Samples were collected from Centro Hospitalar Universitário do Algarve during the period extending from January 2016 to June 2019. p53 and Ki67 expression was assessed immunohistochemically on Formalin Fixed Paraffin-Embedded tissues. Kaplan-Meier analysis were carried out in each group.


The mean age of the 65 patients (38 males and 27 females) was 63 years old. A total of 53 patients underwent resection and 12 to biopsy. 20 patients completed Stupp Protocol. The median survival time for all patients was 42,1 weeks, A total of 53.8% exhibited p53 overexpression (p53+). Median survival time (with 95% confidence intervals) was 26.7 weeks for patients with p53+ tumors and 48.6 weeks for those with p53-negative tumors (p=<0.05). Ki67 >20% was correlated to poor survival however it was not statistically significant.


In our cohort, p53 expression had strong prognostic value. GBM is characterized by extreme heterogeneity which can affect diagnostic accuracy as well the outcome after surgical treatment. A better understanding of the molecular behaviour could help us planning treatment and developing new targets.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.